Evidence & regulatory context
- Mechanism
- Recombinant human MG53 (TRIM72) membrane-repair protein.
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWoundC57BL/6N for eccentric contraction injury; tPA-MG53 transgenic on C57BL/6J background; MG53 knockout; db/dbMale (C57BL/6N eccentric contraction cohort); not stated for other cohortsn = Groups of 10 for the eccentric contraction and recombinant…Intravenous (tail vein) and subcutaneous2 mg/kg intravenously for the time-course study; 0, 0.6, 2,…Intravenous dosing at varying times after injury, still effective at 6 hours; d…
Model: Eccentric contraction-induced skeletal muscle injury (60 tetanic contractions with forced lengthening via sciatic nerve stimulation) and 1 mm through-and-through ear punch wound
Recombinant human MG53 protected against eccentric contraction-induced muscle injury in a time- and dose-dependent manner, and daily subcutaneous dosing from 24 hours after injury improved recovery of contractile function over 28 days versus saline, while transgenic mice with elevated circulating M…
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.